SEC Tracker
Get the app

Arbutus Biopharma ABUS

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 99.1
Press release
  • Reports quarterly results (2.02)
  • Reports an executive or board change (5.02)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Arbutus Biopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. KalVista Pharmaceuticals KALV public float $499M, Jun 30, 2025
  2. CytoDyn CYDY public float $418M, Nov 30, 2025
  3. Elite Pharmaceuticals ELTP public float $534M, Sep 30, 2025
  4. Opko Health OPK public float $540M, Dec 31, 2025
  5. Cryoport CYRX public float $400M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.